Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Cash (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Cash for 7 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 49.39% to $27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, up 107.45% year-over-year, with the annual reading at $11.5 million for FY2025, 107.45% up from the prior year.
  • Change in Cash for Q4 2025 was $27.0 million at Beam Therapeutics, up from -$14.1 million in the prior quarter.
  • The five-year high for Change in Cash was $400.0 million in Q3 2021, with the low at -$263.2 million in Q1 2022.
  • Average Change in Cash over 5 years is $6.2 million, with a median of -$16.4 million recorded in 2023.
  • The sharpest move saw Change in Cash surged 15444.12% in 2021, then plummeted 5422.76% in 2025.
  • Over 5 years, Change in Cash stood at -$54.1 million in 2021, then skyrocketed by 240.9% to $76.3 million in 2022, then soared by 249.97% to $266.9 million in 2023, then tumbled by 80.01% to $53.4 million in 2024, then tumbled by 49.39% to $27.0 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $27.0 million, -$14.1 million, and -$245.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.